Thymic epithelial tumors account for approximately 20% of all mediastinal tumors. Nevertheless, they are rare compared with other malignancies, constituting only 0.2% to 1.5% of all solid tumors.1 The WHO classification system distinguishes thymomas (types A, AB, B1, B2, and B3) from thymic carcinomas (type C) based on the morphology of epithelial tumor cells (with increasing degree of atypia along the spectrum from type A to C), proportion of lymphocytic involvement, and resemblance to normal thymic tissue. Clinically, these diseases can also present differently with a large variety of autoimmune disorders, including myasthenia gravis (30%) occurring in patients with thymoma, whereas patients with thymic carcinoma rarely if ever have autoantibody-induced phenomena.2 Surgery continues to be the most important therapeutic modality for early-stage disease, and a multidisciplinary approach incorporating surgery, radiation, and chemotherapy is recommended in advanced or recurrent disease. Research, however, has been hampered by the rarity of these tumors, which has led to a lack of international consensus surrounding appropriate histopathologic and staging criteria. Much debate has occurred regarding the limitations of the current histologic classifications with regard to both subtype definitions and consistency of diagnosis. The lack of established cell lines and animal models has hindered laboratory investigations, resulting in limited improvements in understanding of tumor biology. In the past decade, newer techniques such as comparative genomic hybridization (CGH), expression array analysis, and next-generation sequencing have resulted in incremental improvements in the understanding of these highly heterogenous tumors. This article focuses on the biological differences between thymomas and thymic carcinomas that may impact treatment decisions, and discusses targeted therapy trials performed to date in the advanced disease setting.
Margaritora S, Cesario A, Cusumano G et al.. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010;89:245–252; discussion 252.
Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485–2492.
Muller-Hermelink HK, Engel P, Kuo TT et al.. Tumours of the thymus. World Health Classification of Tumours, In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press. 2004:146–248.
Chen G, Marx A, Chen WH et al.. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420–429.
Herens C, Radermecker M, Servais A et al.. Deletion (6)(p22p25) is a recurrent anomaly of thymoma: report of a second case and review of the literature. Cancer Genet Cytogenet 2003;146:66–69.
Okumura M, Fujii T, Shiono H et al.. Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg 2008;56:143–150.
Scarpino S, Di Napoli A, Stoppacciaro A et al.. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 2007;149:504–512.
Burbelo PD, Browne SK, Sampaio EP et al.. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 2010;116:4848–4858.
Inoue M, Starostik P, Zettl A et al.. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003;63:3708–3715.
Girard N, Shen R, Guo T et al.. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790–6799.
Kelly RJ, Petrini I, Rajan A et al.. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011;29:4820–4827.
Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202:375–381.
Henley JD, Cummings OW & Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222–224.
Strobel P, Hartmann M, Jakob A et al.. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625–2626.
Bisagni G, Rossi G, Cavazza A et al.. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009;4:773–775.
Giaccone G, Rajan A, Ruijter R et al.. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009;4:1270–1273.
Strobel P, Bargou R, Wolff A et al.. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010;103:196–200.
Yamaguchi H, Soda H, Kitazaki T et al.. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 2006;52:261–262.
Suzuki E, Sasaki H, Kawano O et al.. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351–356.
Ionescu DN, Sasatomi E, Cieply K et al.. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:630–636.
Kurup A, Burns M, Dropcho S et al.. Phase II study of gefitinib treatment in advanced thymic malignancies [abstract]. J Clin Oncol 2005;23(Suppl):Abstract 7068.
Bedano PM, Perkins S, Burns M et al.. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 19087.
Palmieri G, Marino M, Salvatore M et al.. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007;12:757–761.
Pan CC, Chen PC, Wang LS et al.. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003;43:165–172.
Cimpean AM, Raica M, Encica S et al.. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008;190:238–245.
Sasaki H, Yukiue H, Kobayashi Y et al.. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001;31:1038–1040.
Li XF, Chen Q, Huang WX, Ye YB. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009;26:157–160.
Steele NL, Plumb JA, Vidal L et al.. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14:804–810.
Giaccone G, Rajan A, Berman A et al.. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011;29:2052–2059.
Girard N, Teruya-Foldstein J, Payabyab EC et al.. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 2010;5:1439–1446.
Zucali PA, Petrini I, Lorenzi E et al.. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010;116:4686–4695.